At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 09-16 15:38:10 EDT
375.47
-0.18
-0.05%
High379.11Low374.46Vol1.17M
Open376.42D1 Closing375.65Amplitude1.24%
Mkt Cap202.18BTradable Cap201.63BTotal Shares538.48M
T/O441.24MT/O Rate0.22%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analyst Maintains Buy on Amgen, Citing Resilient Fundamentals, Strong Execution, and Late-Stage Pipeline Upside
TIPRANKS  ·  01:05
Analyst Maintains Buy on Amgen, Citing Resilient Fundamentals, Strong Execution, and Late-Stage Pipeline Upside
Sling Therapeutics Raises $123 Million to Advance Thyroid Eye Disease Drug
Reuters  ·  09-16 19:00
Sling Therapeutics Raises $123 Million to Advance Thyroid Eye Disease Drug
Bristol Myers Sues Amgen over Proposed Opdivo Biosimilar
Reuters  ·  09-16 04:25
Bristol Myers Sues Amgen over Proposed Opdivo Biosimilar
Amgen Announces Dividend of R$ 0.31 Per Unit, Payable Sept. 17
Reuters  ·  09-15 20:17
Amgen Announces Dividend of R$ 0.31 Per Unit, Payable Sept. 17
Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market
Bellwether Stocks Movement  ·  09-15 19:30
Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market
Amgen to deploy Veeva Vault CRM globally
TIPRANKS  ·  09-15 19:10
Amgen to deploy Veeva Vault CRM globally
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong
Dow Jones  ·  09-15 16:33
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong
Amgen Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  09-15 04:35
Amgen Inc. Stock Outperforms Competitors on Strong Trading Day
Amgen’s Phase 3 Dazodalibep Study Nears Data Spotlight for Sjögren’s Investors
TIPRANKS  ·  09-15 00:30
Amgen’s Phase 3 Dazodalibep Study Nears Data Spotlight for Sjögren’s Investors
Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China
Dow Jones  ·  09-14 22:04
Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China
FDA Approves Shorter Monitoring Time for Amgen’s Imdelltra First Two Doses
Reuters  ·  09-14 21:06
FDA Approves Shorter Monitoring Time for Amgen’s Imdelltra First Two Doses
Amgen - Imdelltra Monitoring Reduced to 6-8 Hours for First Two Infusions
THOMSON REUTERS  ·  09-14 21:00
Amgen - Imdelltra Monitoring Reduced to 6-8 Hours for First Two Infusions
Amgen - Imdelltra Monitoring Remains 6-8 Hours for Third Dose, 3-4 Hours for Cycles 3-4
THOMSON REUTERS  ·  09-14 21:00
Amgen - Imdelltra Monitoring Remains 6-8 Hours for Third Dose, 3-4 Hours for Cycles 3-4
FDA Approves Reduced Monitoring Time for First Two Doses of Imdelltra®
THOMSON REUTERS  ·  09-14 21:00
FDA Approves Reduced Monitoring Time for First Two Doses of Imdelltra®
Amgen - Patients to Receive Follow-up Assessment After First Two Imdelltra Doses
THOMSON REUTERS  ·  09-14 21:00
Amgen - Patients to Receive Follow-up Assessment After First Two Imdelltra Doses
AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales
Options & Short Sell  ·  09-14 17:14
AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales
Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors
Dow Jones  ·  09-14 16:30
Sino Biopharmaceutical Stock Advances 4.3% in Hong Kong, Outperforms Competitors
GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market
Options & Short Sell  ·  09-14 11:57
GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street
Dow Jones  ·  09-12
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street
Palo Alto, Eaton, Amgen, SpaceX, LMT Trending With Analysts
TIPRANKS  ·  09-12
Palo Alto, Eaton, Amgen, SpaceX, LMT Trending With Analysts

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--